Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952964 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL1161416 | 0.95 | CYP11B1 (0.40) | CYP11B1CYP11B2HCAR2GRIN1GRIN2B | |
| Bromide SCHEMBL1258756 | 0.83 | TRPA1 (0.35) | NOS1 | |
| SCHEMBL2730526 | 0.80 | TRPA1 (0.36) | NOS1 | |
| SCHEMBL13066610 | 0.76 | — | — | |
| SCHEMBL29525051 | 0.74 | — | — | |
| SCHEMBL21909724 | 0.74 | — | — | |
| SCHEMBL20775303 | 0.74 | — | — | |
| Bromide SCHEMBL29020867 | 0.74 | POLB (0.39) | HCAR2 | |
| Bromide SCHEMBL29413316 | 0.74 | POLB (0.39) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250163029-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-11-28 | — | — | US | disclosed |
| US-20240383853-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-11-21 | — | — | US | disclosed |
| EP-4408838-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408533-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-118139842-A | Oximes and their use in the treatment of GBA related diseases | 泽拉丹麦有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118076599-A | Dioxazines and their use in the treatment of GBA related diseases | 泽拉丹麦有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180072674-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2016149324-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY (US) | 2016-09-22 | — | — | WO | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| EP-2432776-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | Chlorion Pharma, Inc. (CA) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | CYP11B1 204/4885CYP11B2 117/4885HCAR2 193/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | CYP11B1 175/4885CYP11B2 159/4885HCAR2 1530/4885 |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | CYP11B1 204/4885CYP11B2 117/4885HCAR2 193/4885 |
| US-20240383853-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | GBA1, GBA2, GBA3 | CYP11B1 1441/4885CYP11B2 1166/4885HCAR2 836/4885 |
| US-20250163029-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF | DPYD, PNPO, TYMP | CYP11B1 508/4885CYP11B2 287/4885HCAR2 2771/4885 |
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | GBA1, GBA2, GBA3 | CYP11B1 3440/4885CYP11B2 3255/4885HCAR2 932/4885 |
| US-20180072674-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRM1, GRIN2A | CYP11B1 3948/4885CYP11B2 3148/4885HCAR2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.